Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TFFP | Common Stock | Purchase | $50K | +43.5K | +43.47% | $1.15 | 143K | Nov 22, 2022 | Direct | F3 |
holding | TFFP | Common Stock | 110K | Nov 22, 2022 | See footnote | F1 | |||||
holding | TFFP | Common Stock | 542K | Nov 22, 2022 | See footnote | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TFFP | Common Stock Purchase Warrants | Purchase | $0 | +21.7K | $0.00 | 21.7K | Nov 22, 2022 | Common Stock | 21.7K | $1.29 | Direct |
Id | Content |
---|---|
F1 | The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund II, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund II, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4. |
F2 | The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4. |
F3 | The reported shares were purchased in a private transaction from TFF Pharmaceuticals, Inc. at a price of $1.15. |